Deciphera Pharmaceuticals, Inc. (DCPH) News
Filter DCPH News Items
DCPH News Results
|Loading, please wait...|
DCPH News Highlights
- For DCPH, its 30 day story count is now at 14.
- Over the past 10 days, the trend for DCPH's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- The most mentioned tickers in articles about DCPH are BEAT, DRUG and MSCI.
Latest DCPH News From Around the Web
Below are the latest news stories about Deciphera Pharmaceuticals Inc that investors may wish to consider to help them evaluate DCPH as an investment opportunity.
No summary available.
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q4 2021 Results - Earnings Call Transcript
Deciphera Pharmaceuticals, Inc. (DCPH) Q4 2021 Earnings Conference Call February 08, 2022, 04:30 PM ET Company Participants Maghan Meyers - SVP, Argot Partners Steve Hoerter - President and CEO Dan Martin - Chief Commercial Officer Tucker Kelly - CFO Conference Call Participants Jessica Fye - JPMorgan Eun Yang - Jefferies...
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Deciphera Pharmaceuticals (DCPH – Research Report), with a price target of $15.00. The company's shares closed last Tuesday at $8.16, close to its 52-week low of $7.36. According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of -2.4% and a 36.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals, Inc., and Global Blood Therapeutics. Deciphera Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $13.75.
Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update. “I am immensely proud of our organization’s achievements in 2021 and believe that we are well positioned for long-term success as we work towards our expected milestones in 2022,” said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. “While the unexpected result
Deciphera Pharmaceuticals press release (DCPH): Q4 GAAP EPS of -$1.51 misses by $0.03.Revenue of $24.2M (+24.2% Y/Y) beats by $0.92M.
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -1.34% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Toronto, A6, based Investment company CIBC Asset Management Inc (Current Portfolio) buys Bank of Nova Scotia, Franco-Nevada Corp, Suncor Energy Inc, NVIDIA Corp, iShares MSCI EAFE ETF, sells Shaw Communications Inc, Progressive Corp, Visa Inc, Allegion PLC, Lightspeed Commerce Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, CIBC Asset Management Inc.
Let us take a look at three biotech/drug companies that are slated to release quarterly results on Feb 8.
WALTHAM, Mass., February 02, 2022--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the following investor conferences: